Hester Biosciences
Stock Snapshot
Price Performance
Vista Outlook
View Technicals Analysis →Basis of our Recommendation
Hester Biosciences is strategically enhancing its manufacturing capabilities and expanding its market presence, particularly in Africa and Asia, which is expected to drive revenue growth in the poultry healthcare division. Management's optimism is supported by the recent licensing of the H9N2 Avian Influenza vaccine, which positions the company to capitalize on increased demand for vaccines. However, challenges such as delays in tender-led programs and raw material cost pressures due to geopolitical factors may temper performance. Vista's financial outlook reflects stable revenue growth and margins, underpinned by Hester's strong competitive position as the second-largest poultry vaccine manufacturer. The company's focus on operational efficiencies and product innovation aligns with Vista's expectations for long-term growth, despite the current valuation indicating a potential value trap. Over the next 12-24 months, Hester's expansion initiatives and product diversification present significant opportunities, while execution risks and regulatory scrutiny remain critical watchpoints
Why We Like This Stock
- Expansion of manufacturing capabilities and market presence in Africa and Asia is expected to drive revenue growth
- Licensing of the H9N2 Avian Influenza vaccine enhances Hester's competitive edge in the poultry healthcare market
- Focus on operational efficiencies and product innovation aligns with long-term growth expectations
Things To Watch Out For
- Delays in tender-led programs within the Animal Healthcare division may impact overall performance
- Raw material cost pressures due to geopolitical factors could affect margins and production capacity
- Execution risks in scaling up vaccine availability in new markets pose potential challenges
Key Parameters
Financial Snapshot
| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 305 | 311 | 333 | 300 | 319 |
| Profit Before Tax (Cr.) | 32 | 40 | 73 | 67 | 71 |
| PBT Margin | 10.5% | 13.0% | 2200.3% | 22.5% | 22.3% |
| Net Profit (Cr.) | 21 | 27 | 58 | 54 | 55 |
| Earnings Per Share | 22.4 | 30.7 | 66.0 | 61.3 | 64.8 |
Analyst Recommendations
No analyst recommendations available.
Company Overview
Show Company Profile
Hester Biosciences Limited manufactures and trades in veterinary vaccines and health products in India and internationally. It operates through two segments, Poultry Healthcare and Animal Healthcare. The company provides poultry vaccines for newcastle disease, infectious bronchitis, infectious bursal, fowl pox, marek's disease, infectious coryza, fowl cholera, inclusion body hepatitis, fowl typhoid, and avian encephalomyelitis. It also offers vaccines for peste des petits ruminants, goat pox, brucella, lumpy skin disease, contagious bovine pleuropneumonia, and contagious caprine pleuropneumonia for cattle, buffalo, sheep, and goats; and diagnostic services. In addition, the company provides animal healthcare products, such as biosecurity solutions, therapeutics, nutritional supplements, and specialised formulations to enhance animal wellness and productivity. Further, it offers various pet care products, including gut health solutions, NSAIDs, joint care formulations, parasiticides, grooming products, and anti-infective formulations; and healthcare products, such as immune boosters, gut health enhancers, farm hygiene, vitamins, minerals, and specialty feed supplements for critical needs comprising disease prevention, growth, and nutritional balance. Additionally, the company provides Silvectant, a hydrogen peroxide and silver nitrate solution for disinfection of poultry sheds; Hestbac, a probiotic supplement to control pathogenic bacteria; Hestflora, a combined probiotic and prebiotic formulation that supports gut health and performance; AmmoStop, a probiotic blend for odour control and respiratory comfort in poultry farms. It also offers INACTIVATED H9N2 vaccine for low pathogenic avian influenza; ICEFT RTU, a ceftiofur formulation for uterine and bacterial infections; and Inomilk Gel, an oral calcium supplement, as well as operates diagnostic labs for poultry. Hester Biosciences Limited was incorporated in 1987 and is headquartered in Mehsana, India.